Karyopharm Therapeutics (KPTI)
NASDAQ:KPTI
KPTI Stock Chart & Stats
$5.48
-$0.04(-5.28%)
At close: 4:00 PM EST
$5.48
-$0.04(-5.28%)
Day’s Range― - ―
52-Week Range$3.51 - $10.99
Previous CloseN/A
Volume220.82K
Average Volume (3M)228.24K
Market Cap
$100.52M
Enterprise Value$219.85M
Total Cash (Recent Filing)$63.74M
Total Debt (Recent Filing)$233.61M
Price to Earnings (P/E)―
Beta1.47
Next Earnings
Apr 30, 2026EPS Estimate
-1.43Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.71
Shares Outstanding18,343,967
10 Day Avg. Volume494,784
30 Day Avg. Volume228,238
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-0.27
Price to Sales (P/S)0.55
P/FCF Ratio-1.07
Enterprise Value/Market Cap2.19
Enterprise Value/Revenue1.51
Enterprise Value/Gross Profit1.57
Enterprise Value/Ebitda-2.80
Forecast
1Y Price Target
$17.20Price Target Upside213.87% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-4.88
Revenue Forecast (FY)$139.06M
Bulls Say, Bears Say
Bulls Say
Capital StructureA recent equity financing materially extends the operating cash runway, reducing near-term funding pressure and lowering the immediate need for dilutive capital.
Late-stage ReadoutPositive top-line SENTRY results for the selinexor plus ruxolitinib combination would act as a high-impact catalyst, likely prompting a rapid re-rating and clearer commercial prospects.
Survival SignalObserved early overall survival benefit in the SENTRY program could support regulatory approval despite mixed primary endpoint results, increasing upside potential for the therapy.
Bears Say
Commercial And Franchise WeaknessThe existing multiple myeloma franchise has underperformed due to limited durability and tolerability concerns, keeping valuation depressed and highlighting commercial risk for new programs.
Co-primary Endpoint FailureSENTRY showed a benefit on spleen volume but failed to improve symptom scores, which undermines the co-primary endpoint strategy and weakens approval prospects.
Regulatory Precedent RiskHistorical cases where agents improved spleen measures but missed symptom endpoints did not progress to regulatory submissions, raising concern that the current data pattern may not meet approval standards.
Karyopharm Therapeutics News
KPTI FAQ
What was Karyopharm Therapeutics’s price range in the past 12 months?
Karyopharm Therapeutics lowest stock price was $3.51 and its highest was $10.99 in the past 12 months.
What is Karyopharm Therapeutics’s market cap?
Karyopharm Therapeutics’s market cap is $100.52M.
When is Karyopharm Therapeutics’s upcoming earnings report date?
Karyopharm Therapeutics’s upcoming earnings report date is Apr 30, 2026 which is in 31 days.
How were Karyopharm Therapeutics’s earnings last quarter?
Karyopharm Therapeutics released its earnings results on Feb 12, 2026. The company reported -$5.71 earnings per share for the quarter, missing the consensus estimate of -$1.994 by -$3.716.
Is Karyopharm Therapeutics overvalued?
According to Wall Street analysts Karyopharm Therapeutics’s price is currently Undervalued.
Does Karyopharm Therapeutics pay dividends?
Karyopharm Therapeutics does not currently pay dividends.
What is Karyopharm Therapeutics’s EPS estimate?
Karyopharm Therapeutics’s EPS estimate is -1.43.
How many shares outstanding does Karyopharm Therapeutics have?
Karyopharm Therapeutics has 18,343,967 shares outstanding.
What happened to Karyopharm Therapeutics’s price movement after its last earnings report?
Karyopharm Therapeutics reported an EPS of -$5.71 in its last earnings report, missing expectations of -$1.994. Following the earnings report the stock price went up 21.303%.
Which hedge fund is a major shareholder of Karyopharm Therapeutics?
Currently, no hedge funds are holding shares in KPTI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Karyopharm Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$17.20 (213.87% Upside)
$17.20 (213.87% Upside)
Hedge Fund Trend
Decreased
By 8.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 6.9%
Last 30 Days ▲ 7.8%
Last 30 Days ▲ 7.8%
News Sentiment
Bullish
Bullish news 78%
Bearish news 22%
Bearish news 22%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-53.70%
12-Months-Change
Fundamentals
Return on Equity
77.87%
Trailing 12-Months
Asset Growth
-28.56%
Trailing 12-Months
Company Description
Karyopharm Therapeutics
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma, and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company has license agreement with Menarini Group to develop and commercialize NEXPOVIO for human oncology indications in Europe, including the United Kingdom; Latin America; and other countries. Its oral SINE compounds also designed to force nuclear accumulation in the levels of multiple tumor suppressor and growth regulatory proteins. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.
KPTI Company Deck
KPTI Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presents a mixed but measured outlook: strong near‑term clinical catalysts (SENTRY in March and EXPORT EC042 mid‑2026), encouraging early efficacy and tolerability data, modest product revenue growth and demonstrated cost discipline. Offsetting these positives are a constrained cash runway (into Q2 2026), large GAAP losses driven by debt‑related and noncash items, elevated interest expense, and dependence on binary Phase III readouts to drive future value. Overall, the balance of significant upside potential from pending pivotal data against material near‑term financial constraints yields a neutral stance.View all KPTI earnings summariesKPTI Stock 12 Month Forecast
Average Price Target
$17.20
▲(213.87% Upside)
Technical Analysis
Actinium Pharmaceuticals
―
Bioxcel Therapeutics
―
Lantern Pharma
―
Century Therapeutics
―
Medicus Pharma Ltd
―
Ownership Overview
4.45% Insiders
20.90% Mutual Funds
31.29% Other Institutional Investors
39.27% Public Companies and
Individual Investors